Antiphospholipid Syndrome Committee of the Brazilian Society of Rheumatology position statement on the use of direct oral anticoagulants (DOACs) in antiphospholipid syndrome (APS)

Antiphospholipid Syndrome Committee of the Brazilian Society of Rheumatology position statement on the use of direct oral anticoagulants (DOACs) in antiphospholipid syndrome (APS)

Abstract Background The term Direct Oral Anticoagulants (DOACs) refers to a group of drugs that inhibit factor Xa or thrombin. Even though their use for treating different thrombotic or prothrombotic conditions is increasing recently, there is no compelling evidence indicating that those medications...

Full description

Bibliographic Details
Main Authors: Gustavo Guimarães Moreira Balbi, Marcelo de Souza Pacheco, Odirlei Andre Monticielo, Andreas Funke, Adriana Danowski, Mittermayer Barreto Santiago, Henrique Luiz Staub, Jozelia Rêgo, Danieli Castro Oliveira de Andrade
Format: Article
Language:English
Published: BMC 2020-05-01
Series:Advances in Rheumatology
Subjects:
Antiphospholipid syndrome
Factor Xa inhibitors
Rivaroxaban
Apixaban
Edoxaban
Antithrombins
Online Access:http://link.springer.com/article/10.1186/s42358-020-00125-9

Internet

http://link.springer.com/article/10.1186/s42358-020-00125-9

Similar Items